Fluxion Biosciences Expands into Asian Market | GenomeWeb

NEW YORK (GenomeWeb News) – Cell-analysis tool company Fluxion Biosciences said today that it has expanded its sales and service network into Asia through a pair of distribution agreements and an instrument sale.

Fluxion, based in South San Francisco, Calif., said that it signed a distribution agreement for its BioFlux instrument line with Korea's DI Biotech, and a second agreement with Novel Science to sell both the BioFlux and IonFlux platforms in Japan.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: genome-wide transcriptome analysis of brain samples from people with autism spectrum disorder, flounder genome, and more.

Researchers used T-cell transfer therapy to target mutation KRAS, according to the New York Times.

The US Senate has passed the 21st Century Cures Act, which would provide a funding boost at NIH while overhauling FDA policies.

Bloomberg reports that President-elect Donald Trump is considering Jim O'Neill for Food and Drug Administration commissioner.